Experience the Molbio advantage

Molbio Diagnostics is a pioneering Indian in-vitro diagnostics (IVD) company with a global footprint. We have deep expertise in development, production, and commercialization of pathbreaking diagnostic platforms that address the clinical need gaps and are deployed at Point-of-Care (POC), resource-limited settings. Our flagship product, Truenat, has been successfully deployed across 85+ countries and has positively impacted millions of lives. Bigtec Labs is the R&D division of Molbio and functions as an innovation engine with a multidisciplinary team of 100 scientists and engineers, who excel in translating scientific ideas into market-ready products.

About EDGE 2.0

This is the second edition of the pioneering partnership program created by Molbio and Bigtec to collaborate with growth-stage MedTech startups and support the scaling of high-impact healthcare innovations within focused thematic areas.

Structured as an intensive 12-week program, EDGE is designed to accelerate technology development and enable faster Go-To-Market (GTM) traction. Through focused mentorship, strategic guidance, and hands-on support, participating companies gain practical insights across commercialization strategy, regulatory pathways, manufacturing scale-up, and market access.

At the conclusion of the program, Molbio selectively engages with a few cohort participants for future partnerships. These may include bridge funding for co-development, licensing opportunities, as well as sales and distribution collaborations. Each participant benefits from bespoke, one-on-one guidance tailored to their product maturity and growth stage, ensuring highly contextual and outcome-driven support.

The program follows a hybrid format, featuring intermittent visits to Molbio’s state-of-the-art facilities in Bangalore and Goa. All program-related expenses, including travel and accommodation, are fully covered by Molbio.

Some snapshots of EDGE 2.0

Call Areas

Point-of-Care (POC), ideally rapid, or Near Care Devices or Critical Technology Elements (CTEs) which can be used for human diagnostics -and are in early stages of development (TRL 2 to TRL 6). These may include the following, but not limited to:

1

Novel concepts that address diagnosis of infectious diseases and Non-Communicable Diseases (NCDs)

2

Novel concepts in genetic testing, such as SNP detection approaches using isothermal amplification methods

3

Antimicrobial Resistance (AMR) detection including genotypic and rapid phenotypic Antimicrobial Susceptibility Test (AST)

Program Value

Leverage the expertise of Molbio and Bigtec to cross the ‘valleys of death’

Masterclass and Workshops

With global leaders in public health and MedTech industry in areas of innovation, strategy, regulatory, GTM, and sales

R&D and Manufacturing

Technical expertise and rapid MVP to production through best-in-class DFM

Validation and Regulatory

Well-established global ecosystem of validation partners and regulatory expertise

Partnership Opportunity

Access to Centre of Excellence (CoE) and potential funding opportunities for transition to scale

Sales

Connecting with our expansive distribution network in 85+ countries

Visits

In-person workshops at Bigtec, Bangalore, and production sites at Molbio, Goa